SWISS BIOTECH™
1NATION1CLUSTER
News Bulletin
No. 21
April
2017

In cooperation with the CTI
KTT-Support
National thematic networks
Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra
Swiss Confederation
Commission for Technology and Innovation CTI

Editorial

Daniel Gygax

Following the visit of the SBA in South Korea in July 2016, a delegation of representatives from South Korean academia and companies travelled to Switzerland in April. The National Thematic Network Swiss Biotech was invited by CTI to organize an interesting two day programme for the Korean guests. Visits at the ETH Zürich, the BioTechnopark Schlieren, the FHNW Basel and the Roche campus were complemented by networking and presentation opportunities for the Swiss and South Korean biotech industry and academic resarchers. The exchange will support and foster the submission of projects within the 3rd call launched in March 2017.



Contents

CTI Launches 3rd Swiss-Korean Innovation Project Call

Following the first and second successful calls of 2015 and 2016, the Korea Institute for Advancement of Technology (KIAT) and the Commission for Technology and Innovation (CTI) are launching a third call for joint innovation projects between Switzerland and South Korea.

Who is the call aimed at?

- The call for joint innovation projects is aimed at companies and research institutions in Switzerland and South Korea (consortia) looking to carry out a joint science-based innovation project.
- It is aimed for Swiss and South Korean companies which see the two countries as a major market and research locations; and which want to take advantage of the benefit from KIAT and CTI funding.
- The Call is open for all topics, but focuses on the development of products and services within (1) biotechnology, (2) medtech and (3) information and communication technology (ICT).

What conditions apply?

This is an international, bilateral funding measure subject to the funding rules of KIAT and the CTI. Details are published in the call documentation. The call was launched 8 March 2017.

The funding organisations will be glad to advise interested parties on request.

Which criteria must be met?

- The basic requirements for setting up a consortium must be met; in particular, the skills and expertise of the Swiss and South Korean partners should be complementary.
- The planned project brings benefits to the project partners in both countries.
- The planned innovation project is clearly market-oriented.
- Please refer to CTI's website (www.kti.admin.ch) for full conditions.

What is the call procedure?

The call is being conducted in a single stage procedure. Consideration should be given to the following points:

- Launch of the call is 08 March 2017.
- The closing date for submissions is 19 June 2017.
- The joint application together with the CTI application form for Swiss partners and the KIAT application form for partners from South Korea must be written in English. The consortia submits simultaneously to both funding agencies (joint application and CTI application to the CTI, joint application and KIAT application to KIAT).
- Notification of the evaluation results is beginning of October 2017

Contacts: Alain Dietrich: alain.dietrich@kti.admin.ch; Barbara Pfluger: barbara.pfluger@kti.admin.ch

NTN partners: Swiss Biotech Association, biotechnet switzerland

Korean Company Profiles and Co-operation Interests

Company	Your Fields of Research	Your Competencies	Website	In which technology fields of Swiss partners are you interested?
ATI Biosystems	Lab automation	System design, development and manufacturer of automated systems. We have dedicated software engineers and system engineers capable of producing and operating various automated systems. Our greatest competencies is that we have the resources to develop customized lab automation that can satisfy the unmet needs in the bio-technology automation industry.	www.bioautomation.co.kr	Partners in the fields of bioprinting of organoids (organ tissue). More specifically, we want to partner with a research institution in the fields of testing drugs or treatment on organ tissues (ex. liver tissue) that requires “cell printing.” We also want to find a partner with experience in valve and dispensing technology to dispense cells.
HWANGSUNG Co.	Sensor - 3DTLSENS (3D TouchLess safety SENSor)	The project comprises the design and development of a new distributed 3DTLSENS able to detect the variation of the capacity caused by a change of the surrounding conditions. The 3DTLSENS system is composed by grounded plate and a stripe, which acts as another plate, thus forming a capacitor. An electric field is generated if the stripe is polarized to a certain voltage value. The electric field can be affected by a surrounding variation like, for example, the presence of an object which causes the variation of the capacitance between the stripe and ground. If the polarized voltage is a frequency-controlled signal, the variation of the electric field can be easily detected by closing the signal generator in a loop control.	http://eng.electricstep.kr/index.php?language=eng	Research Institutes within industry that need 3D Sensors(3DTLSENS)
KAIST, Department of Bio&Brain Engineering	Microtechnology, MEMS	Micro Sensors for Human Physiological Stress	http://mems.kaist.ac.kr	Human Stress & Emotion Montitoring
Kangwon National University, Systems Immunology	Therapeutic target discovery; therapeutic and diagnostic antibody and antibody conjugate development	Discovery & development of biodrugs including mAb and ADCs Applied protein chemistry	http://si.kangwon.ac.kr/bbs/content.php?co_id=sub07_2_3	Institute or biotech company interested in enrichment of therapeutic pipelines and targeted drug discovery
Kyungpook National Unversity, Laser Application Center, Institute of Advanced Convergence Technology	Biomedical Optics, Medical devices Laser processing	Laser-Tissue Interaction(diagnosis/therapy); Laser joining(metal-ceramic)		Laser applications
NGeneBio Co., Ltd.	Next generation sequencing (NGS) based in vitro diagnostics (IVD) product development Clinical bioinformatics & SW development Companion Diagnostics (Cancer)	Clinical bioinformatics Clinical NGS data analysis pipeline & SW development NGS-IVD product development	http://ngenebio.com/	NGS assay/panel developer which is interested in IVD product development combined with IVD analysis SW Cancer genetic marker-targeting drug developer which is interested in solution for companion molecular diagnostics Commercial genetic testing labs which is interested in development of NGS-based IVD testing assay Pharmacogenomics developer which is interested in companion diagnostics
OBELAB, Inc.	Neuroimaging		www.obelab.com	Biotechnology, Bio signal data analysis, Big data manipulation
PCL Inc.	In Vitro Diagnostics		www.pclchip.com	Medical device for POCT
Qurient, Co., Ltd.	Cancer, Immuno-oncology	Based on biology and pharmacology, we want to strengthen our pipelines.	www.qurient.com	Companies that can pursue an added-value for our program. Partnership is considering co-development for risk sharing. Qurient oncology program: TAM RTK Inhibitor (preclinical), CDK7 Inhibitor (lead optimization) In licensing: Small molecule with anticancer effect in discovery stage
SEIL TECHNO CORP.	IT, OPTIC R&D	IT, OPTIC R&D	www.stvision.co.kr	
Seoul National University, Mechanical Engineering	Microfluidics, organ on a chip	Organ on a chip	http://mbel.snu.ac.kr/professor.html	Biotech and medtech interested in a Organ-on-a-chip microfluidic paltform.
Seoul National University, Molecular Medicine & Biopharmaceutical Sciences	Therapeutic target discovery: in-situ identification of phenotypic cell surface markers	IP-MS and chemical crosslinking analytic platforms discoverying ligand-receptor & Ab-antigen pairs	http://tcpl.snu.ac.kr/	Institute or Biotech interested in enrichment of therapeutic pipelines and targeted drug discovery
UXEnterprise	Woman’s healthcare	Smart wearable device for prevent women's disease	www.ybrain.com	Healthcare, biomedical , biosignal analysis, hospitals,pharmaceutical company
Ybrain Inc.	Medical Treatment Device based on Non-Invasive Brain Stimulation	Home Treatment + Mobile Services	www.yonsei.ac.kr	Stroke Rehabilitation
Yonsei University, Material Science and Engineering	Medical technology	Gas sensor		Sensor chip fabrication For the preparation of “S. Korea-Switzerland Joint R&D projects”, we are currently conducting a technological collaboration with the partner manufacturing sensors in the Switzerland, and we are planning to take part in the “3rd S. Korea-Switzerland Call for Joint R&D projects” to discuss

Program of the Korean Delegation

Participants of the Korean Delegation

- Ki Hyun KIM, HWANGSUNG Co., Ltd, Executive Director
- Hu Sang SHIN, HWANGSUNG Co., Ltd, Executive Officer
- Hanseok YUN, OBELAB, Inc., Chief Operating Officer
- Noo Li JEON, Seoul National University, Professor
- Seohyun AHN, Qurient, Co., Ltd., Director
- YoungJoon MOON, NGeneBio Co., Ltd., Director
- Soyoun KIM, PCL Inc., CEO
- Ye Chan SHIN, ATI Biosystems, Manager
- Young-Ho CHO, KAIST, Professor
- Ye Jin LEE, UXEnterprise, CEO
- Kristine M. KIM, Kangwon National University, Professor
- Eugene C YI, Seoul National University, Professor
- Jung Seok KIM, SEIL TECHNO CORP., PRESIDENT
- Wooyoung, Lee, Yonsei university, Professor
- Yong-Sahm CHOE, iSenLab Inc., CEO
- Gu-In JUNG, Kyungpook National Unversity, Senior Researcher
- Su-Won KIM, Kyungpook National Unversity, Senior Researcher
- Jihyun LIM, Swiss Embassy, Deputy Head(STO)
- Somi YOON, Korea Institute for Advancement of Technology KIAT, Senior Researcher

An interesting program has been organized together with and for the CTI by members of the NTN Swiss Biotech.

Wednesday, 19 April 2017:

Morning at ETH Zürich-Hönggerberg with presentations by:

- Prof. Dr. Ernst Hafen, ETH Zürich, Health Data Ownership
- Hr. Michael Stucky, Wyss Translational Center, Presentation of the Center
- Dr. Maximilian Emmert, Wyss Translational Center, Life Matrix
- Dr. Daniel Stekhoven, ETH/Nexus, Clinical Bioinformatics
- Prof. Dr. Bernd Wollscheid, ETH Zürich, Proteomics
- Prof. Dr. Noo Li Jeon, Seoul National University, Microfluidic Platform for Organ-on-a-chip

Afternoon within the premises of Molecular Partners in Schlieren:

- Dr. Reto Näf, Topadur AG, Wound Healing
- Dr. Silke Schneider, Competence Center Personalized Medicine ETH/UZH, Introduction and Activities of the Competence Center
- Dr. Olivier Frey, Insphero AG, 3D-Tissues ¨
- Prof. Dr. Markus Seeger, University Zürich, Antibiotics Platform of NTN Swiss Biotech
- Prof. Dr. Michael Raghunath, UAS, Wädenswil, Zürich, TEDD Platform of NTN Swiss Biotech
- Soyoun Kim, PCLInc., Novel 3D biomarker immobilization technology
- Prof. Dr. Young-Ho Cho, KAIST, Skin Patches for Human Stress Monitoring

Thursday, 20 April 2017

Morning on the premises of F. Hoffmann-La Roche in Basel:

- Mrs. Patricia Fischer, Roche, General Information
- Dr. Franz Schuler, Laboratory visit

Afternoon at the UAS NW in Basel:

- Dr. Lope Florez, Genedata Basel, Software and Services
- Dr. Thomas Hafen, Bühlmann Laboratories, in vitro Diagnostics
- Paul R. Hofer, Hutman Diagnostics, Molecular Diagnostics
- Prof. Dr. Falko Schlottig, UAS NW-Switzerland, School of Life Sciences, Research at Universities of Applied Sciences
- Prof. Dr. Veronika Butterweck, UAS NW-Switzerland, Plant and Herb Medicine
- Dr. Young Joon Moon, NgeneBio Co. Ltd., Next Generation based Sequencing based cancer based IVD assay
- Dr. Seohyun Ahn, Qurient Co. Ltd., Introduction to Oncology Program

Contact:

NTN-SwissBiotech
Editor C. Kroll - info@swissbiotech.org
Advertising H. Bihlman - bihlman@swissbiotech.org
Published 3 times a year (print or pdf.)

Main Office, Zürich
Swiss Biotech Association
Stauffacherstrasse 16
8004 Zürich

Office Romandie
Swiss Biotech Association
Rue Haldimand 15
1003 Lausanne